Articles

RSS

Washington, D.C. - Wolters Kluwer Health, a leading global provider of drug and medical information services and content to the pharmaceutical and biotechnology industries, recently announced a partnership with CambridgeSoft of Cambridge, Mass., to market chemical structure search tools for drug discovery scientists and pharmaceutical chemists.

Recently, at the annual meeting of the American Chemical Society (ACS), the companies demonstrated their first joint product, a software module that allows scientists to use ChemDraw(R), the leading chemical-drawing software, to search by chemical structure for all of the compounds in the existing Adis R&D Insight(R) database. Marketed by Wolters Kluwer Health, Adis R&D Insight is the industry's most authoritative pipeline intelligence tool that features a database of more than 20,000 compounds.

CambridgeSoft's technology converts chemical compound names into their associated chemical structures and makes them immediately searchable. Using the new module, drug discovery scientists can query the vast, text-based Adis R&D Insight database using their own language. The resulting benefit is that users can evaluate a structure in the context of related compounds.

"Using our new structure searching module, scientists can check to see if a target molecule is already in development or if it's near clinical trials," said John Monahan, President and CEO of Wolters Kluwer Health, Pharma Solutions. "By harnessing the power of ChemDraw and Adis R&D Insight, we've made it easier for scientists to identify a potentially competitive compound earlier in the development process."

"CambridgeSoft is pleased to be partnering with Wolters Kluwer Health," said Michael G. Tomasic, Chairman and CEO of CambridgeSoft. "Combining content provided by Wolters Kluwer Health with the leading chemical structure search technology, including ChemOffice and ChemDraw, from CambridgeSoft enhances the ability of the scientific community to search, analyze, and make decisions relevant to the direction of the research."

ChemDraw is the leading chemical-drawing program on the market with more than 500,000 users. Updated daily, Adis R&D Insight captures new drugs and drug therapies in development, globally, from a wealth of sources and monitors each one throughout its product lifecycle.

Available in September, the new chemical structure search module is being marketed to existing ChemDraw users and subscribers to Adis R&D Insight for Chemists. For more information, visit http://www.adisinsight.com or contact Adis Business Intelligence by calling +1 267 757-3421, ext. 1, or via email at bi-support@adis.com.

SOURCE: CambridgeSoft Corporation